MoonLake Immunotherapeutics (MLTX) Total Current Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $46.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 92.29% year-over-year to $46.1 million; the TTM figure through Mar 2026 stood at $46.1 million (up 92.29% YoY), while the FY2025 annual figure was $45.5 million, up 102.46% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $46.1 million, up from $45.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $202.8 million in Q1 2022, with the low at $3.9 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $12.3 million (2024), against an average of $30.0 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 337883.77% in 2022, then slumped 96.41% in 2023.
• MoonLake Immunotherapeutics' Total Current Liabilities stood at $7.7 million in 2022, then soared by 30.01% to $10.0 million in 2023, then surged by 125.4% to $22.5 million in 2024, then soared by 102.46% to $45.5 million in 2025, then rose by 1.4% to $46.1 million in 2026.
• Business Quant data shows MLTX's Total Current Liabilities at $46.1 million in Q1 2026, $45.5 million in Q4 2025, and $48.4 million in Q3 2025.